Search Videos and More
News
Study Uncovers Role of Ultraviolet Radiation in Development of Rare Leukemia in the Skin
A change of scenery can restore one's outlook, but for some precancerous cells, a journey from the caves of the bone marrow to the sunny climes of the skin can trigger genetic changes that are a harbinger of cancer, according to a new study by researchers at Dana-Farber Cancer Institute, Brigham and Women's Hospital, and the Broad Institute of MIT and Harvard.
Symposium
2023 ASCO Highlights
Dana-Farber physician-scientists shared research and clinical advances at the 2023 Annual Meeting of the American Society of Clinical Oncologists (ASCO).
News
Dana-Farber/Boston Children's Again Ranked Among the Best Pediatric Cancer Programs in the Nation
U.S. News & World Report has named Dana-Farber/Boston Children's Cancer and Blood Disorders Center the #2 pediatric program in the nation in its 2023-24 Best Children's Hospitals report.
Video
ASCO 2023: Breast Cancer Research Presented by Paolo Tarantino, MD
Data from more than 8,000 patients with stage 1A triple-negative breast cancer finds improved 5-year breast-cancer specific survival in those treated with adjuvant chemotherapy whose tumors measured between 1-2 cm.
Video
ASCO 2023: Prostate Cancer Research Presented by Praful Ravi, MB BCHIR, MRCP
ICECAP collaboration was the largest study looking at the prognostic value of PSA nadir in localized prostate cancer, finding a PSA level of less than 0.1 could provide an early prognosis signal.
Video
ASCO 2023: Breast Cancer Research Presented by Jennifer Ligibel, MD
Women with breast cancer shed pounds thanks to telephone-based weight loss program, clinical trial finds.
Video
ASCO 2023: Kidney Cancer Research Presented by Toni Choueiri, MD
We learn from negative study results as well as from positive ones. Phase 3 study by Dana-Farber's Toni Choueiri, MD, shows that rechallenge with PD-L1 inhibitors in second-line therapy for advanced kidney cancer has no benefit.
Video
ASCO 2023: Treating NUT Carcinoma Research Presented by Jia Luo, MD
Dana-Farber's Jia Luo, MD, details on findings from the NUT Carcinoma Registry on initial chemotherapy for locally advanced and metastatic disease.
Video
ASCO 2023: Breast Cancer Research Presented by Sara Tolaney, MD
Data shows antibody-drug conjugate offers significant survival benefit for patients with HR-positive/HER2-negative metastatic breast cancer.
Video
ASCO 2023: Head And Neck Research Presented by Glenn Hanna, MD
Encouraging anti-tumor activity for patients with metastatic head & neck squamous cell carcinoma who are HPV-negative and treated with bifunctional EGFR/TGF-beta inhibitor BCA101 w/pembrolizumab.
News
New Study Suggests Simple Test Could Detect Breast and Ovarian Cancer Risk Without Genetic Sequencing
Researchers from Dana-Farber Cancer Institute, Brigham and Women’s Hospital, and Medical University of Lodz have found a way to detect increased cancer risk associated with BRCA1 and BRCA2 mutations without genetic sequencing, according to a new study in Nature Communications.
News
Treatment Decisions in New Era of Individualized Therapy For Metastatic Hormone-Sensitive Prostate Cancer Guided by Dana-Farber Case Study
Oncologists have traditionally prescribed androgen deprivation therapy (ADT) alone for patients with metastatic hormone-sensitive prostate cancer (mHSPC).